News & Events about Amneal Pharmaceuticals Inc.
ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET Orion and Amneal enter strategic partnership Orion receives exclusive licence to commercialise Amneals generic products in Europe, Australia and New Zealand Orion Corporation today announced it has signed a long-term license agreement with ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced it has signed a long-term license agreement with Orion Corporation (OMXH: ORNBV & ORNAV) to commercialize a number of Amneals complex generic products. Under the partnership agreement, Orion is Amneals...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that the Company has successfully launched 26 new generic products in 2022. In the fourth quarter of 2022, the Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal...
Business Wire
2 months ago
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) today announced that the management team will attend the following investor conferences: Piper Sandler 34th Annual Healthcare Conference December 1, 2022 New York, New York 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 San...
Business Wire
2 months ago
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for IPX203 for the treatment of Parkinsons disease (PD). IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release...